IDEAYA Biosciences (IDYA) Cash from Financing Activities (2018 - 2026)

IDEAYA Biosciences has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $1.2 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $1.2 million, down 95.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (down 98.64% YoY), and the FY2025 annual result was $29.8 million, down 95.6% from the prior year.
• Cash from Financing Activities came in at $1.2 million for Q1 2026 at IDEAYA Biosciences, down from $2.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $349.1 million in Q1 2024 to a low of $301000.0 in Q3 2025.
• The 5-year median for Cash from Financing Activities is $2.9 million (2023), against an average of $68.7 million.
• Across the five-year window, Cash from Financing Activities soared 43385.8% in 2023 and plunged 99.89% in 2025, its largest moves.
• IDEAYA Biosciences' Cash from Financing Activities stood at $324000.0 in 2022, then jumped by 43385.8% to $140.9 million in 2023, then sank by 98.05% to $2.8 million in 2024, then retreated by 22.63% to $2.1 million in 2025, then plunged by 44.55% to $1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.2 million (Q1 2026), $2.1 million (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.